1. Name of the medicinal product
Revlimid 2.5 mg hard capsules
Revlimid 5 mg hard capsules
Revlimid 7.5 mg hard capsules
Revlimid 10 mg hard capsules
Revlimid 15 mg hard capsules
Revlimid 25 mg hard capsules
2. Qualitative and quantitative composition
• Each capsule contains 2.5 mg of lenalidomide.
Excipient(s) with known effect:
Each capsule contains 73.5 mg of lactose, anhydrous.
• Each capsule contains 5 mg of lenalidomide.
Excipient(s) with known effect:
Each capsule contains 147 mg of lactose, anhydrous.
• Each capsule contains 7.5 mg of lenalidomide.
Excipient(s) with known effect:
Each capsule contains 144.5 mg of lactose, anhydrous.
• Each capsule contains 10 mg of lenalidomide.
Excipient(s) with known effect:
Each capsule contains 294 mg of lactose, anhydrous.
• Each capsule contains 15 mg of lenalidomide.
Excipient(s) with known effect:
Each capsule contains 289 mg of lactose, anhydrous.
• Each capsule contains 25 mg of lenalidomide.
Excipient(s) with known effect:
Each capsule contains 200 mg of lactose, anhydrous.
For a full list of excipients, see section 6.1.
3. Pharmaceutical form
Hard capsule.
Blue-green/white capsules marked “REV 2.5 mg”.
White capsules marked “REV 5 mg”.
Pale yellow/white capsules marked “REV 7.5 mg”.
Blue-green/pale yellow capsules marked “REV 10 mg”.
Pale blue/white capsules marked “REV 15 mg”.
White capsules marked “REV 25 mg”.
4. Clinical particulars
4.1 Therapeutic indications
Multiple myeloma
Revlimid in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.
Myelodysplastic syndromes
Revlimid is indicated for the treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.
4.2 Posology and method of administration
Revlimid treatment should be supervised by a physician experienced in the use of anti-cancer therapies (see section 4.4, karyotype).
Posology
Multiple myeloma
Recommended dose
The recommended starting dose of lenalidomide is 25 mg orally once daily on days 1-21 of repeated 28-day cycles. The recommended dose of dexamethasone is 40 mg orally once daily on days 1-4, 9-12, and 17-20 of each 28-day cycle for the first 4 cycles of therapy and then 40 mg once daily on days 1-4 every 28 days. Dosing is continued or modified based upon clinical and laboratory findings (see section 4.4). Prescribing physicians should carefully eva luate which dose of dexamethasone to use, taking into account the condition and disease status of the patient.
Lenalidomide treatment must not be started if the Absolute Neutrophil Counts (ANC) < 1.0 x 109/l, and/or platelet counts < 75 x 109/l or, dependent on bone marrow infiltration by plasma cells, platelet counts < 30 x 109/l.
Recommended dose adjustments during treatment and restart of treatment
Dose adjustments, as summarised below, are recommended to manage grade 3 or 4 neutropenia or thrombocytopenia, or other grade 3 or 4 toxicity judged to be related to lenalidomide.
• Dose reduction steps
Starting dose
|
25 mg
|
Dose level -1
|
15 mg
|
Dose level -2
|
10 mg
|
Dose level -3
|
5 mg
|
• Thrombocytopenia
When platelets
|
Recommended Course
|
First fall to < 30 x 109/l
Return to ≥ 30 x 109/l
|
Interrupt lenalidomide treatment
Resume lenalidomide at Dose Level -1
|
For each subsequent drop below 30 x 109/l
Return to ≥ 30 x 109/l
|
Interrupt lenalidomide treatment
Resume lenalidomide at next lower dose level (Dose Level -2 or -3) once daily. Do not dose below 5 mg once daily.
|
• Neutropenia
When neutrophils
|
Recommended Course
|
First fall to < 0.5 x 109/l
Return to ≥ 0.5 x 109/l when neutropenia is the only observed toxicity
|
Interrupt lenalidomide treatment
Resume lenalidomide at Starting Dose once daily
|
Return to ≥ 0.5 x 109/l when dose-dependent haematological toxicities other than neutropenia are observed
|
Resume lenalidomide at Dose Level -1 once daily
|
For each subsequent drop below < 0.5 x 109/l
Return to ≥ 0.5 x 109/l
|
Interrupt lenalidomide treatment
Resume lenalidomide at next lower dose level (Dose Level -1, -2 or -3) once daily. Do not dose below 5 mg once daily.
|
In case of neutropenia, the physician should consider the use of growth factors in patient management.
Myelodysplastic syndromes
Lenalidomide treatment must not be started if the Absolute Neutrophil Counts (ANC) < 0.5 x 109/l and/or platelet counts < 25 x 109/l.
Recommended dose
The recommended starting dose of lenalidomide is 10 mg orally once daily on days 1-21 of repeated 28-day cycles. Dosing is continued or modified based upon clinical and laboratory findings (see section 4.4)
Recommended dose adjustments during treatment and restart of treatment
Dose adjustments, as summarized below, are recommended to manage grade 3 or 4 neutropenia or thrombocytopenia, or other grade 3 or 4 toxicity judged to be related to lenalidomide.
Starting Dose
|
10 mg once daily on days 1-21 every 28 days
|
Dose Level -1
|
5.0 mg once daily on days 1-28 every 28 days
|
Dose Level -2
|
2.5 mg once daily on days 1-28 every 28 days
|
Dose Level -3
|
2.5 mg every other day 1-28 every 28 days
|
For patients who are dosed initially at 10 mg and who experience thrombocytopenia or neutropenia:
• Thrombocytopenia
When platelets
|
Recommended Course
|
Fall to < 25 x 109/l
Return to ≥ 25 x 109/l - < 50 x 109/l on at least 2 occasions for ≥ 7 days or when the platelet count recovers to ≥ 50 x 109/l at any time
|
Interrupt lenalidomide treatment
Resume lenalidomide at next lower dose level (Dose Level -1, -2 or -3)
|
• Neutropenia
When neutrophils
|
Recommended Course
|
Fall to < 0.5 x 109/l
Return to ≥ 0.5 x 109/l
|
Interrupt lenalidomide treatment
Resume lenalidomide at next lower dose level (Dose Level -1, -2 or -3)
|
For patients who experience other toxicities
For other grade 3 or 4 toxicities judged to be related to lenalidomide, stop treatment and restart at next lower dose level when toxicity has resolved to ≤ grade 2 depending on the physician's discretion.
Lenalidomide interruption or discontinuation should be considered for grade 2 or 3 skin rash. Lenalidomide must be discontinued for angioedema, grade 4 rash, exfoliative or bullous rash, or if Stevens-Johnson syndrome or toxic epidermal necrolysis is suspected, and should not be resumed following discontinuation from these reactions.
Discontinuation of lenalidomide
Patients without at least a minor erythroid response within 4 months of therapy initiation, demonstrated by at least a 50% reduction in transfusion requirements or, if not transfused, a 1g/dl rise in haemoglobin, should discontinue lenalidomide treatment.
Special populations
Paediatric population
The safety and efficacy of Revlimid in children aged 0-17 years have not yet been established. No data are available.
Elderly population
The effects of age on the pharmacokinetics of lenalidomide have not been studied. Lenalidomide has been used in clinical trials in multiple myeloma patients up to 86 years of age and in myelodysplastic syndromes patients up to 95 years of age (see section 5.1).
The percentage of multiple myeloma patients aged 65 or over was not significantly different between the lenalidomide/dexamethasone and placebo/dexamethasone groups. No overall difference in safety or efficacy was observed between these patients and younger patients, but greater pre-disposition of older individuals cannot be ruled out.
For myelodysplastic syndromes patients treated with lenalidomide, no overall difference in safety and efficacy was observed between patients aged over 65 and younger patients.
Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it would be prudent to monitor renal function.
Patients with renal impairment
Lenalidomide is substantially excreted by the kidney, therefore care should be taken in dose selection and monitoring of renal function is advised.
No dose adjustments are required for patients with mild renal impairment and multiple myeloma or myelodysplastic syndromes. The following dose adjustments are recommended at the start of therapy for patients with moderate or severe impaired renal function or end stage renal disease.
• Multiple myeloma
Renal Function (CLcr)
|
Dose Adjustment
(Days 1 to 21 of repeated 28- day cycles)
|
Moderate renal impairment
(30 ≤ CLcr < 50 ml/min)
|
10 mg once daily1
|
Severe renal impairment
(CLcr < 30 ml/min, not requiring dialysis)
|
7.5 mg once daily2,3
15 mg every other day3
|
End Stage Renal Disease (ESRD)
(CLcr < 30 ml/min, requiring dialysis)
|
5 mg once daily. On dialysis days, the dose should be administered following dialysis.
|
1 The dose may be escalated to 15 mg once daily after 2 cycles if patient is not responding to treatment and is tolerating the treatment.
2 In countries where the 7.5 mg capsule is available.
3 The dose may be escalated to 10 mg once daily if the patient is tolerating the treatment.
After initiation of lenalidomide therapy, subsequent lenalidomide dose modification in renally impaired patients should be based on individual patient treatment tolerance, as described above.
• Myelodysplastic syndromes
Renal Function (CLcr)
|
Dose Adjustment
|
Moderate renal impairment
(30 ≤ CLcr < 50 ml/min)
|
Starting dose
|
5 mg once daily
(days 1-21 of repeated 28-day cycles)
|
Dose level -1
|
2.5 mg once daily
(days 1-28 of repeated 28-day cycles)
|
Dose level -2
|
2.5 mg once every other day
(days 1-28 of repeated 28-day cycles)
|
Severe renal impairment
(CLcr < 30 ml/min, not requiring dialysis)
|
Starting dose
|
2.5 mg once daily
(days 1-21 of repeated 28-day cycles)
|
Dose level -1
|
2.5 mg every other day
(days 1-28 of repeated 28-day cycles)
|
Dose level -2
|
2.5 mg twice a week
(days 1-28 of repeated 28-day cycles)
|
End Stage Renal Disease (ESRD)
(CLcr < 30 ml/min, requiring dialysis)
On dialysis days, the dose should be administered following dialysis.
|
Starting dose
|
2.5 mg once daily
(days 1-21 of repeated 28-day cycles)
|
Dose level -1
|
2.5 mg every other day
(days 1-28 of repeated 28-day cycles)
|
Dose level -2
|
2.5 mg twice a week
(days 1-28 of repeated 28-day cycles)
|
Patients with hepatic impairment
Lenalidomide has not formally been studied in patients with impaired hepatic function and there are no specific dose recommendations.
Method of administration
Revlimid capsules should be taken at about the same time each day. The capsules should not be opened, broken or chewed. The capsules should be swallowed whole, preferably with water, either with or without food. If less than 12 hours has elapsed since missing a dose, the patient can take the dose. If more than 12 hours has elapsed since missing a dose at the normal time, the patient should not take the dose, but take the next dose at the normal time on the following day.
4.3 Contraindications
• Women who are pregnant.
• Women of childbearing potential unless all of the conditions of the Pregnancy Prevention Programme are met (see sections 4.4 and 4.6).
• Hypersensitivity to the active substance or to any of the excipients, listed in section 6.1.
4.4 Special warnings and precautions for use
Pregnancy warning
Lenalidomide is structurally related to thalidomide. Thalidomide is a known human teratogenic active substance that causes severe life-threatening birth defects. Lenalidomide induced in monkeys malformations similar to those described with thalidomide (see sections 4.6 and 5.3). If lenalidomide is taken during pregnancy, a teratogenic effect of lenalidomide in humans is expected.
The conditions of the Pregnancy Prevention Programme must be fulfilled for all patients unless there is reliable evidence that the patient does not have childbearing potential.
Criteria for women of non-childbearing potential
A female patient or a female partner of a male patient is considered to have childbearing potential unless she meets at least one of the following criteria:
• Age ≥ 50 years and naturally amenorrhoeic for ≥ 1 year*
• Premature ovarian failure confirmed by a specialist gynaecologist
• Previous bilateral salpingo-oophorectomy, or hysterectomy
• XY genotype, Turner syndrome, uterine agenesis.
*Amenorrhoea following cancer therapy or during lactation does not rule out childbearing potential.
Counselling
For women of childbearing potential, lenalidomide is contraindicated unless all of the following are met:
• She understands the expected teratogenic risk to the unborn child
• She understands the need for effective contraception, without interruption, 4 weeks before starting treatment, throughout the entire duration of treatment, and 4 weeks after the end of treatment
• Even if a woman of childbearing potential has amenorrhea she must follow all the advice on effective contraception
• She should be capable of complying with effective contraceptive measures
• She is informed and understands the potential consequences of pregnancy and the need to rapidly consult if there is a risk of pregnancy
• She understands the need to commence contraceptive measures as soon as lenalidomide is dispensed following a negative pregnancy test
• She understands the need and accepts to undergo pregnancy testing every 4 weeks except in case of confirmed tubal sterilisation
• She acknowledges that she understands the hazards and necessary precautions associated with the use of lenalidomide.
For male patients taking lenalidomide, pharmacokinetic data has demonstrated that lenalidomide is present in human semen at extremely low levels during treatment and is undetectable in human semen 3 days after stopping the substance in the healthy subject (see section 5.2). As a precaution, all male patients taking lenalidomide must meet the following conditions:
• Understand the expected teratogenic risk if engaged in sexual activity with a pregnant woman or a woman of childbearing potential
• Understand the need for the use of a condom if engaged in sexual activity with a pregnant woman or a woman of childbearing potential not using effective contraception (even if the man has had a vasectomy), during treatment and for 1 week after dose interruptions and/or cessation of treatment.
• Understand that if his female partner becomes pregnant whilst he is taking Revlimid or shortly after he has stopped taking Revlimid, he should inform his treating physician immediately and that it is recommended to refer the female partner to a physician specialised or experienced in teratology for eva luation and advice.
The prescriber must ensure that for women of childbearing potential:
• The patient complies with the conditions of the Pregnancy Prevention Programme, including confirmation that she has an adequate level of understanding
• The patient has acknowledged the aforementioned conditions.
Contraception
Women of childbearing potential must use one effective method of contraception for 4 weeks before therapy, during therapy, and until 4 weeks after lenalidomide therapy and even in case of dose interruption unless the patient commits to absolute and continuous abstinence confirmed on a monthly basis. If not established on effective contraception, the patient must be referred to an appropriately trained health care professional for contraceptive advice in order that contraception can be initiated.
The following can be considered to be examples of suitable methods of contraception:
• Implant
• Levonorgestrel-releasing intrauterine system (IUS)
• Medroxyprogesterone acetate depot
• Tubal sterilisation
• Sexual intercourse with a vasectomised male partner only; vasectomy must be confirmed by two negative semen analyses
• Ovulation inhibitory progesterone-only pills (i.e. desogestrel)
Because of the increased risk of venous thromboembolism in patients with multiple myeloma taking lenalidomide and dexamethasone, and to a lesser extent in patients with myelodysplastic syndromes taking lenalidomide monotherapy, combined oral contraceptive pills are not recommended (see also section 4.5). If a patient is currently using combined oral contraception the patient should switch to one of the effective method listed above. The risk of venous thromboembolism continues for 4−6 weeks after discontinuing combined oral contraception. The efficacy of contraceptive steroids may be reduced during co-treatment with dexamethasone (see section 4.5).
Implants and levonorgestrel-releasing intrauterine systems are associated with an increased risk of infection at the time of insertion and irregular vaginal bleeding. Prophylactic antibiotics should be considered particularly in patients with neutropenia.
Copper-releasing intrauterine devices are generally not recommended due to the potential risks of infection at the time of insertion and menstrual blood loss which may compromise patients with neutropenia or thrombocytopenia.
Pregnancy testing
According to local practice, medically supervised pregnancy tests with a minimum sensitivity of 25 mIU/ml must be performed for women of childbearing potential as outlined below. This requirement includes women of childbearing potential who practice absolute and continuous abstinence. Ideally, pregnancy testing, issuing a prescription and dispensing should occur on the same day. Dispensing of lenalidomide to women of childbearing potential should occur within 7 days of the prescription.
Prior to starting treatment
A medically supervised pregnancy test should be performed during the consultation, when lenalidomide is prescribed, or in the 3 days prior to the visit to the prescriber once the patient had been using effective contraception for at least 4 weeks. The test should ensure the patient is not pregnant when she starts treatment with lenalidomide.
Follow-up and end of treatment
A medically supervised pregnancy test should be repeated every 4 weeks, including 4 weeks after the end of treatment, except in the case of confirmed tubal sterilisation. These pregnancy tests should be performed on the day of the prescribing visit or in the 3 days prior to the visit to the prescriber.
Men
Lenalidomide is present in human semen at extremely low levels during treatment and is undetectable in human semen 3 days after stopping the substance in the healthy subject (see section 5.2). As a precaution, and taking into account special populations with prolonged elimination time such as renal impairment, all male patients taking lenalidomide should use condoms throughout treatment duration, during dose interruption and for 1 week after cessation of treatment if their partner is pregnant or of childbearing potential and not using effective contraception (even if the man has had a vasectomy).
Additional precautions
Patients should be instructed never to give this medicinal product to another person and to return any unused capsules to their pharmacist at the end of treatment.
Patients should not donate blood during therapy or for 1 week following discontinuation of lenalidomide.
Educational materials, prescribing and dispensing restrictions
In order to assist patients in avoiding foetal exposure to lenalidomide, the Marketing Authorisation Holder will provide educational material to health care professionals to reinforce the warnings about the expected teratogenicity of lenalidomide, to provide advice on contraception before therapy is started, and to provide guidance on the need for pregnancy testing. The prescriber must inform male and female patients about the expected teratogenic risk and the strict pregnancy prevention measures as specified in the Pregnancy Prevention Programme and provide patients with appropriate patient educational brochure, patient card and/or equivalent tool in accordance to the national implemented patient card system. A national controlled distribution system has been implemented in collaboration with each National Competent Authority. The controlled distribution system includes the use of a patient card and/or equivalent tool for prescribing and/or dispensing controls, and the collecting of detailed data relating to the indication in order to monitor closely the off-label use within the national territory. Ideally, pregnancy testing, issuing a prescription and dispensing should occur on the same day. Dispensing of lenalidomide to women of childbearing potential should occur within 7 days of the prescription and following a medically supervised negative pregnancy test result.
Other special warnings and precautions for use
Cardiovascular disorders
Myocardial infarction
Myocardial infarction has been reported in patients receiving lenalidomide, particularly in those with known risk factors. Patients with known risk factors – including prior thrombosis – should be closely monitored, and action should be taken to try to minimize all modifiable risk factors (eg. smoking, hypertension, and hyperlipidaemia).
Venous and arterial thromboembolic events
In patients with multiple myeloma, the combination of lenalidomide with dexamethasone is associated with an increased risk of venous thromboembolism (predominantly deep vein thrombosis and pulmonary embolism) and arterial thromboembolism (predominantly myocardial infarction and cerebrovascular event) – see sections 4.5 and 4.8.
In patients with myelodysplatic syndromes, treatment with lenalidomide monotherapy was also associated with a risk of venous thromboembolism (predominantly deep vein thrombosis and pulmonary embolism), but to a lesser extent than in patients with multiple myeloma – see sections 4.5 and 4.8.
Consequently, patients with known risk factors for thromboembolism – including prior thrombosis – should be closely monitored. Action should be taken to try to minimize all modifiable risk factors (e.g. smoking, hypertension, and hyperlipidaemia). Concomitant administration of erythropoietic agents or previous history of thromboembolic events may also increase thrombotic risk in these patients. Therefore, erythropoietic agents, or other agents that may increase the risk of thrombosis, such as hormone replacement therapy, should be used with caution in multiple myeloma patients receiving lenalidomide with dexamethasone. A haemoglobin concentration above 12 g/dl should lead to discontinuation of erythropoietic agents.
Patients and physicians are advised to be observant for the signs and symptoms of thromboembolism. Patients should be instructed to seek medical care if they develop symptoms such as shortness of breath, chest pain, arm or leg swelling. Prophylactic antithrombotic medicines should be recommended, especially in patients with additional thrombotic risk factors. The decision to take antithrombotic prophylactic measures should be made after careful assessment of an individual patient's underlying risk factors.
If the patient experiences any thromboembolic events, treatment must be discontinued and standard anticoagulation therapy started. Once the patient has been stabilised on the anticoagulation treatment and any complications of the thromboembolic event have been managed, the lenalidomide treatment may be restarted at the original dose dependent upon a benefit risk assessment. The patient should continue anticoagulation therapy during the course of lenalidomide treatment.
Neutropenia and thrombocytopenia
The major dose limiting toxicities of lenalidomide include neutropenia and thrombocytopenia. A complete blood cell count, including white blood cell count with differential count, platelet count, haemoglobin, and haematocrit should be performed at baseline, every week for the first 8 weeks of lenalidomide treatment and monthly thereafter to monitor for cytopenias. A dose reduction may be required (see section 4.2). In case of neutropenia, the physician should consider the use of growth factors in patient management. Patients should be advised to promptly report febrile episodes. Co-administration of lenalidomide with other myelosuppressive agents should be undertaken with caution.
• Multiple myeloma
The combination of lenalidomide with dexamethasone in multiple myeloma patients is associated with a higher incidence of grade 4 neutropenia (5.1% in lenalidomide/dexamethasone-treated patients compared with 0.6% in placebo/dexamethasone-treated patients; see section 4.8). Grade 4 febrile neutropenia episodes were observed infrequently (0.6% in lenalidomide/dexamethasone-treated patients compared to 0.0% in placebo/dexamethasone treated patients; see section 4.8).
The combination of lenalidomide with dexamethasone in multiple myeloma patients is associated with a higher incidence of grade 3 and grade 4 thrombocytopenia (9.9% and 1.4%, respectively, in lenalidomide/dexamethasone-treated patients compared to 2.3% and 0.0% in placebo/dexamethasone-treated patients; see section 4.8). Patients and physicians are advised to be observant for signs and symptoms of bleeding, including petechiae and epistaxes, especially in case of concomitant medication susceptible to induce bleeding (see section 4.8 Haemorrhagic disorders).
• Myelodysplastic syndromes
Lenalidomide treatment in myelodysplastic syndromes patients is associated with a higher incidence of grade 3 and 4 neutropenia and thrombocytopenia compared to patients on placebo (see section 4.8).
Renal impairment
Lenalidomide is substantially excreted by the kidney. Therefore care should be taken in dose selection and monitoring of renal function is advised in patients with renal impairment (see section 4.2).
Thyroid disorders
Cases of hypothyroidism and cases of hyperthyroidism have been reported. Optimal control of co-morbid conditions influencing thyroid function is recommended before start of treatment. Baseline and ongoing monitoring of thyroid function is recommended.
Peripheral neuropathy
Lenalidomide is structurally related to thalidomide, which is known to induce severe peripheral neuropathy. At this time, the neurotoxic potential of lenalidomide associated with long-term use cannot be ruled out.
Tumour lysis syndrome
Because lenalidomide has anti-neoplastic activity the complications of tumour lysis syndrome may occur. The patients at risk of tumour lysis syndrome are those with high tumour burden prior to treatment. These patients should be monitored closely and appropriate precautions taken.
Allergic reactions
Cases of allergic reaction/hypersensitivity reactions have been reported (see section 4.8). Patients who had previous allergic reactions while treated with thalidomide should be monitored closely, as a possible cross-reaction between lenalidomide and thalidomide has been reported in the literature.
Severe skin reactions
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported. Lenalidomide must be discontinued for exfoliative or bullous rash, or if SJS or TEN is suspected, and should not be resumed following discontinuation for these reactions. Interruption or discontinuation of lenalidomide should be considered for other forms of skin reaction depending on severity. Patients with a history of severe rash associated with thalidomide treatment should not receive lenalidomide.
Lactose intolerance
Revlimid capsules contain lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
Unused capsules
Patients should be advised never to give this medicinal product to another person and to return any unused capsules to their pharmacist at the end of the treatment.
Second primary malignancies
An increase of second primary malignancies (SPM) ha